Avicanna Inc. (AVCN:CA) Discusses Strategic Pivot, Business Pillars, and Pharmaceutical Pipeline Progress Transcript
Summarize this article with:
SA Transcripts157.39K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Avicanna Inc. (AVCN:CA) Discusses Strategic Pivot, Business Pillars, and Pharmaceutical Pipeline Progress December 17, 2025 10:00 AM EST Company Participants Aras Azadian - Co-Founder, CEO & DirectorKarolina Urban Presentation Aras AzadianCo-Founder, CEO & Director Well, good morning, everyone. Thank you for joining us for the year-end review and corporate update of Avicanna Inc. It's a pleasure to be hosting you this year. Giving you an update on another very exciting and progressive year. I'll be presenting this morning. My name is Aras Azadian, I'm the CEO and Founder of Avicanna Inc. I'm joined by Dr. Karolina Urban, who is leading our research and medical affairs, essentially scientific affairs here at Avicanna. We'll take about 25 minutes or so to provide a corporate update, and we'll cover a bunch of the -- a number of the topics that are included within various business pillars. And at the end, we'll save about 5 to 10 minutes for Q&A, which you can actually start adding your questions throughout the presentation in the tab below. So customary disclaimer notice regarding forward-looking statements. This will be all available, we'll provide the presentation to the attendees. Just a bit of an overview on Avicanna for some of you that may not be as familiar with the company or sort of its evolution. We started in 2016 originally as a pharmaceutical drug development and drug delivery company out here in Toronto in the MaRS Discovery District, part of a Johnson & Johnson incubator. We spent the first few years focused on pharmaceutical development. We had a number of drug candidates. And because we were taking a pharmaceutical pathway, we focus on proprietary drug delivery systems and patentable technologies that we can then take through clinical development. In 2021, we pivoted strategically to actually take some of these formulations and products into